Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease description

Pathophysiology

6 evidence topics · 7 sources

Notch pathway cross-talk and overexpression

“Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote